Volatile organic compounds in breath as marker of asthma and COPD: studies on methodologic aspects

Completed

• Conditions: airway obstruction; COPD; 10006436

• Registration Number: NL-OMON31214
• Lead Sponsor: Medisch Centrum Leeuwarden

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 12 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 150

Inclusion Criteria

Study 1;COPD patients:
•Adults between 40-65 years
•Lungfunction: FEV1/VC< 70% and FEV1 30-80%pred. (GOLD II-IV ) (21)
•Actual smoker(>10 cigarettes/day, >10 packyears)
Controls:
•Adults between 40-65 years
•Healthy with a negative history on lung diseases or any other illness.
•Prebronchodilator FEV1 > 80% predicted, FEV1/FVC > 0.70 (22)
•Actual smoker(>10 cigarettes/day, > 10 packyears);Study 2;COPD patients:
•Adults between 40-65 years
•Lungfunction: FEV1/VC< 70% and FEV1 30-80%pred (GOLD II-IV ) (21)
•Non-smoker(> 1 year, > 10 packyears)
Controls:
•Adults between 40-65 years
•Healthy with a negative history on lung diseases or any other illness.
•Prebronchodilator FEV1 > 80% predicted, FEV1/FVC > 0.70 (22)
•Actual non-smoker(> 1 year);Study 3;COPD patients:
•Adults between 40-65 years
•Lungfunction: FEV1/VC< 70% and FEV1 30-80%pred (GOLD II-IV ) (21)
•Non-smoker(>1 year, > 10 packyears)
Asthma patients:
•Adults between 40-65 years
•episodic chest symptoms, documented reversibility in FEV1 by 400 µg inhaled salbutamol > 12 %pred or airway hyperresponsiveness (PC20 methacholine < 8 mg/ml) [15], with or without atopy
•Non-smoker(>1 year,< 10 packyears)

Exclusion Criteria

•Other pulmonary diseases
•Pregnancy
•Diabetes mellitus (documented in the past)
•Hypercholesterolaemia (documented in the past)
•Exacerbation < 6 weeks
•Any infection (especially of the airways) in the last 4 weeks
•Inhalation medication < 4 hours
parodontitis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Study 1: the change in smellprint before and after smoking a cigarette.<br /><br>Study 2: the change in smellprint before, during and after oxygen supply<br /><br>Study 3: the change in smellprint before and after nebulisation of<br /><br>salbutamol/ipratropiumbromide </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>